Tracells develops a non-invasive stool test that utilizes RNA profiles from intestinal cells to diagnose inflammatory bowel diseases (IBD) with high precision. This technology provides detailed insights into inflammation severity and location, reducing the need for invasive procedures like endoscopies and enabling personalized therapy monitoring.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing and monitoring inflammatory bowel diseases (IBD) often requires invasive procedures like endoscopies and biopsies, which are uncomfortable for patients and can be costly. Existing non-invasive blood and fecal tests lack the specificity to accurately diagnose IBD and pinpoint the location and severity of inflammation.
Solution
Tracells offers a non-invasive stool test that analyzes RNA profiles from intestinal cells shed into the stool to diagnose IBD with high precision. The test leverages advanced transcriptomics and an AI-driven classifier to provide detailed insights into inflammation severity and location. This approach aims to reduce the need for invasive procedures, enable personalized therapy monitoring, and provide colonoscope-equivalent biometric data through a convenient, home-based test. The technology utilizes a patented method to enhance signal detection and improve diagnostic accuracy.
Target Audience
The primary target audience includes gastroenterologists and other healthcare providers who diagnose and manage patients with IBD, as well as patients seeking a less invasive diagnostic option.
Features
- Non-invasive stool sample collection for patient convenience
- RNA profiling of intestinal cells to capture the patient's transcriptome
- AI-driven analysis to determine inflammation severity and location
- ~1000-gene analysis for highly accurate diagnosis
- Monitoring capabilities for proactive disease management
- Provides colonoscope-equivalent biometric data